## **Christoph Kornauth**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7392852/publications.pdf Version: 2024-02-01



CHRISTORN KORNALITH

#	Article	IF	CITATIONS
1	Epithelial–mesenchymal transition in hepatocellular carcinoma. Future Oncology, 2009, 5, 1169-1179.	2.4	287
2	Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nature Medicine, 2013, 19, 481-487.	30.7	199
3	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2012, 36, 844-850.	3.7	177
4	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 2018, 132, 694-706.	1.4	132
5	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	4.6	130
6	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. Food and Chemical Toxicology, 2014, 72, 312-321.	3.6	77
7	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
8	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 2017, 130, 2499-2503.	1.4	59
9	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. Metallomics, 2014, 6, 1616-1625.	2.4	58
10	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. Science of the Total Environment, 2015, 506-507, 644-655.	8.0	50
11	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia. Investigative Radiology, 2018, 53, 403-408.	6.2	45
12	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood, 2018, 132, 2389-2400.	1.4	45
13	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	2.4	42
14	Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Scientific Reports, 2019, 9, 13783.	3.3	41
15	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia, 2019, 33, 696-709.	7.2	40
16	Behavior of platinum( <scp>iv</scp> ) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	2.4	39
17	Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Advances, 2017, 1, 352-356.	5.2	29
18	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. Metallomics, 2018, 10, 388-396.	2.4	29

#	Article	IF	CITATIONS
19	The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. Kidney International, 2015, 88, 332-340.	5.2	27
20	Extravasation of Pt-based chemotherapeutics – bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). Metallomics, 2015, 7, 508-515.	2.4	27
21	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica, 2020, 105, 435-447.	3.5	27
22	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. Medicine (United States), 2015, 94, e2388.	1.0	24
23	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood, 2021, 137, 3495-3506.	1.4	22
24	Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. PLoS ONE, 2018, 13, e0205195.	2.5	19
25	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood, 2018, 132, 1936-1950.	1.4	18
26	Interleukinâ€6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Experimental Dermatology, 2016, 25, 305-310.	2.9	16
27	Transformed mucosaâ€associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reactionâ€based clonality analysis. British Journal of Haematology, 2019, 186, 448-459.	2.5	16
28	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. Cancers, 2020, 12, 9.	3.7	15
29	ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS. International Journal of Molecular Sciences, 2020, 21, 2095.	4.1	14
30	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone Bâ€cell lymphoma of the mucosaâ€associated lymphoid tissue (MALT lymphoma). Hematological Oncology, 2018, 36, 62-67.	1.7	12
31	STAT5 is Expressed in CD34+/CD38â^ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers, 2020, 12, 1021.	3.7	12
32	Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter. Blood, 2021, 138, 1345-1358.	1.4	12
33	Podocyte RNA sequencing reveals Wnt- and ECM-associated genes as central in FSGS. PLoS ONE, 2020, 15, e0231898.	2.5	10
34	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers, 2021, 13, 5592.	3.7	9
35	The Phenotypic Characterization of the Human Renal Mononuclear Phagocytes Reveal a Co-Ordinated Response to Injury. PLoS ONE, 2016, 11, e0151674.	2.5	7
36	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica, 2021, 106, 2251-2256.	3.5	7

Christoph Kornauth

#	Article	IF	CITATIONS
37	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nature Communications, 2021, 12, 7190.	12.8	7
38	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. Biology, 2021, 10, 1206.	2.8	3
39	Tissue distribution of epirubicin after severe extravasation in humans. Cancer Chemotherapy and Pharmacology, 2021, 88, 203-209.	2.3	2
40	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. Blood, 2019, 134, 807-807.	1.4	2
41	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. Blood, 2016, 128, 4252-4252.	1.4	2
42	Major response of PNH to an AML chemotherapy protocol. Annals of Hematology, 2018, 97, 1487-1488.	1.8	1
43	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	1.4	1
44	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
45	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. Blood, 2019, 134, 4037-4037.	1.4	1
46	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	5.3	1
47	T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?. Frontiers in Oncology, 2022, 12, 805449.	2.8	1
48	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	1.4	0
49	Abstract 2689: High-content imaging and single-cell analysis of drug response ex vivo is predictive of clinical outcome for hematologic cancer patients. , 2019, , .		0
50	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	1.4	0